Sulfate IMT in Ulcerative Colitis Study
Note: Recruitment for this study is on hold currently due to the COVID-19 pandemic.
Gut bacteria (intestinal microbiota) may be responsible for causing or perpetuating inflammation in ulcerative colitis. One possible way that gut bacteria may be tied to inflammation is through the production of hydrogen sulfide gas (H2S). Excess H2S can promote inflammation. Intestinal microbiota transplant (IMT) may be a way to treat UC by changing the gut bacteria.
This study is examining how daily IMT capsules from healthy individuals with low or undetectable amounts of the bacteria that make H2S affect ulcerative colitis. The main goal of the study is to see if we can change the gut bacteria to decrease H2S potential production. We are also looking at how this affects the inflammation and symptoms as well.
This is a randomized placebo controlled trial, which means that there is a 50/50 chance a participant would get IMT capsules or placebo. Because the study is blinded, the participants and the study team do not know who is getting the active therapy. The study consists of 8 weeks of two capsules a day, followed by a four week observation period. After that, participants can choose to opt into an open label trial of IMT capsules for another eight weeks (this time no placebo!). The basic criteria for qualification are below:
- Age > 18
- Ulcerative colitis affecting more than 15cm of your colon
- Active inflammation on a recent endoscopy (within three months) on stable medications.
Most medications can be continued while on this study if they are at stable doses and there is still active inflammation in the colon. If you are interested in learning more or seeing if you qualify for this study, contact the study coordinator, Daria Kozysa.